期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

进展期胃癌分子靶向治疗 被引量：1

Molecular targeted therapy of advancedgastric cancer
原文传递
导出
摘要 进展期胃癌化疗效果不佳。分子靶向治疗是近年来进展期胃癌综合治疗的新手段。目前这些策略主要包括针对表皮生长因子受体（EGFR）通道的靶向治疗、针对血管内皮生长因子通道的靶向治疗、口服小分子靶向药物等。近期有关HER2、EGFR、VEGF、mTOR信号通路的靶向药物曲妥珠单抗、西妥昔单抗、贝伐单抗、阿帕替尼、索拉非尼、舒尼替尼、拉帕替尼、RAD001（everolimus）等综合治疗进展期胃癌的报道结果令人鼓舞。 Efficacy of chemotherapy for advanced gastric cancer is unsatisfactory. Molecular targeted therapies have emerged as a novel approach to the treatment of advanced gastric cancer in recent years. These therapeutic strategies include targeting EGFR signal transduction pathway, anti-angiogenesis therapy, multi-target molecular targeted drugs. Targeted drugs such as trastuzumab, cetuximab, bevacizumab, apatinib, sorafenib sunitinib, lapatinib and everolimus which are targeting HER2, EGFR, VEGF and mTOR pathway, are applied in the comprehensive treatment of advanced gastric cancer, and their therapeutic effects are encouraging.
作者 王润洁 石晓燕 黄薇 刘超英
机构地区 无锡市人民医院肿瘤科
出处 《国际肿瘤学杂志》 CAS 2012年第1期50-53,共4页 Journal of International Oncology
关键词 胃肿瘤 分子靶向治疗 Stomach neoplasms Molecular targeted therapy
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Bang YL, Van Cutsem E, Feyereislova A, et al. Trastuzumab in com- bination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer ( ToGA ) : a phase 3, open-label, randomized controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 2Barok M, Tanner M, Koninki K, et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett, 2011, 306(2) :171-179.
  • 3Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res, 2011, 17(15) :5060-5070.
  • 4Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol, 2007, 18(3) :510-517.
  • 5刘慧龙,张小田,徐建明,沈琳,宋三泰,王金万,梁军,徐农,白玉贤,王杰军,凌焱,李玉霞.西妥昔单抗联合卡培他滨和顺铂一线治疗晚期胃癌及相关预测因子的研究[J].临床肿瘤学杂志,2009,14(5):385-389. 被引量：12
  • 6Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analy-sis of cetuximab combined with modified FOLFOX6 in advanced gas- tric cancer. Br J Cancer, 2009, 100(2) :298-304 .
  • 7Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinote- can, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-orien- ted phase II study. Ann Oncol, 2011, 22(6) :1358-1366.
  • 8Shah MA, Ramanathan RK, Ilson DH, et al. Muhicenter phase II study of irinotccan, cisplatin, and bevacizumab in patients with meta- static gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol, 2006, 24 (33) :5201-5206.
  • 9Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol, 2011, 29(7) :868-874.
  • 10Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of meta- static or advanced gastric and gastroesophageal junction adenocarci- noma: ECOG 5203. J Clin Oncol, 2010, 28(18) :2947-2951.

二级参考文献14

  • 1Shia J,Klimstra DS,Li AR,et al.Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:an immunohistochemical and chromogenic in situ hybridization study[J].Mod Pathol,2005,18:1350-1356.
  • 2Kim MA,Lee HS,Lee HE,et al.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52:738-746.
  • 3Yamada A,Saito N,Kameoka S,et al.Clinical significance of epidermal growth factor(EGF) expression in gastric cancer[J].Hepatogastroenterology,2007,54:1049-1052.
  • 4Celikel C,Eren F,Gulluoglu B,et al.Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas:prognostic implications[J].Pathol Oncol Res,2007,13:215-226.
  • 5Pino MS,Shrader M,Baker CH,et al.Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib(iressa) in human pancreatic cancer cell lines[J].Cancer Res,2006,66:3802-3812.
  • 6Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359:1757-1765.
  • 7Lee KH,Lee JS,Suh C,et al.Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer.An analysis of 140 cases[J].Cancer,1995,75:2794-2801.
  • 8Han S,Park SR,Lee K,et al.Phase Ⅱ study and biomarker analysis of cetuximab in combination with oxaliplatin,5-fluorouracil,leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer[J].J Clin Oncol,2008,26:a4549.
  • 9Lordick F,Lorenzen S,Hegewisch-Becker S,et al.Cetuximab plus weekly oxaliplatin/5FU/FA(FUFOX) in 1st line metastatic gastric cancer.Final results from a multicenter phase Ⅱ study of the AIO upper GI study group[J].J Clin Oncol,2007,25:4526a.
  • 10Pinto C,Di Fabio F,Siena S,et al.Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma(FOLCETUX study)[J].Ann Oncol,2007,18:510-517.

共引文献11

同被引文献4

引证文献1

二级引证文献14

国际肿瘤学杂志
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部